一例罕见的晚期化生性乳腺癌对舒妥珠单抗治疗有反应

IF 0.2 Q4 ONCOLOGY
Sharlene Dong , Yisheng Fang , Samira Syed
{"title":"一例罕见的晚期化生性乳腺癌对舒妥珠单抗治疗有反应","authors":"Sharlene Dong ,&nbsp;Yisheng Fang ,&nbsp;Samira Syed","doi":"10.1016/j.cpccr.2023.100239","DOIUrl":null,"url":null,"abstract":"<div><p>Metaplastic breast cancer is a rare variant of breast cancer with an extremely poor prognosis and limited treatment options. While standard chemotherapy has limited efficacy in treating metaplastic breast cancer, targeted therapies, immune modulating agents and antibody-drug conjugates may be promising alternatives. In this case report, we present a 72-year-old female diagnosed with metastatic triple negative metaplastic breast cancer who failed multiple lines of therapy including immunotherapy with atezolizumab and nab-paclitaxel but was able to achieve a sustained clinical response for nearly one year with the novel antibody drug conjugate Sacituzumab govitecan. Although Sacituzumab govitecan has been studied in metastatic triple negative breast cancer, its efficacy in treating metaplastic breast cancer has not yet been evaluated. To our knowledge, this report represents the first documented case of Sacituzumab govitecan being effectively used to treat metaplastic breast cancer.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"10 ","pages":"Article 100239"},"PeriodicalIF":0.2000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A rare case of advanced metaplastic breast carcinoma with response to treatment with Sacituzumab govitecan\",\"authors\":\"Sharlene Dong ,&nbsp;Yisheng Fang ,&nbsp;Samira Syed\",\"doi\":\"10.1016/j.cpccr.2023.100239\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Metaplastic breast cancer is a rare variant of breast cancer with an extremely poor prognosis and limited treatment options. While standard chemotherapy has limited efficacy in treating metaplastic breast cancer, targeted therapies, immune modulating agents and antibody-drug conjugates may be promising alternatives. In this case report, we present a 72-year-old female diagnosed with metastatic triple negative metaplastic breast cancer who failed multiple lines of therapy including immunotherapy with atezolizumab and nab-paclitaxel but was able to achieve a sustained clinical response for nearly one year with the novel antibody drug conjugate Sacituzumab govitecan. Although Sacituzumab govitecan has been studied in metastatic triple negative breast cancer, its efficacy in treating metaplastic breast cancer has not yet been evaluated. To our knowledge, this report represents the first documented case of Sacituzumab govitecan being effectively used to treat metaplastic breast cancer.</p></div>\",\"PeriodicalId\":72741,\"journal\":{\"name\":\"Current problems in cancer. Case reports\",\"volume\":\"10 \",\"pages\":\"Article 100239\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current problems in cancer. Case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666621923000236\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621923000236","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

化生性乳腺癌是一种罕见的乳腺癌变体,预后极差,治疗选择有限。虽然标准化疗在治疗化生乳腺癌方面的疗效有限,但靶向治疗、免疫调节剂和抗体-药物偶联物可能是有希望的替代方案。在本病例报告中,我们报告了一位72岁的女性,被诊断为转移性三阴性化生性乳腺癌,她多次治疗失败,包括使用阿特唑单抗和nab-紫杉醇的免疫治疗,但使用新型抗体药物偶联Sacituzumab govitecan,她能够获得持续近一年的临床反应。虽然Sacituzumab govitecan已经在转移性三阴性乳腺癌中进行了研究,但其治疗化生性乳腺癌的疗效尚未得到评估。据我们所知,该报告是第一个记录在案的Sacituzumab govitecan有效用于治疗化生乳腺癌的病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A rare case of advanced metaplastic breast carcinoma with response to treatment with Sacituzumab govitecan

Metaplastic breast cancer is a rare variant of breast cancer with an extremely poor prognosis and limited treatment options. While standard chemotherapy has limited efficacy in treating metaplastic breast cancer, targeted therapies, immune modulating agents and antibody-drug conjugates may be promising alternatives. In this case report, we present a 72-year-old female diagnosed with metastatic triple negative metaplastic breast cancer who failed multiple lines of therapy including immunotherapy with atezolizumab and nab-paclitaxel but was able to achieve a sustained clinical response for nearly one year with the novel antibody drug conjugate Sacituzumab govitecan. Although Sacituzumab govitecan has been studied in metastatic triple negative breast cancer, its efficacy in treating metaplastic breast cancer has not yet been evaluated. To our knowledge, this report represents the first documented case of Sacituzumab govitecan being effectively used to treat metaplastic breast cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
0
审稿时长
96 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信